Articles

GSK and MD Anderson enter into cancer immune therapy deal potentially worth more than $335 million

Under terms of the agreement, MD Anderson grants GSK exclusive worldwide rights to develop and commercialize the antibodies, which activate OX40 on the surface of T cells
Written byJeffrey Bouley
| 2 min read

HOUSTON—The University of Texas MD Anderson Cancer Center and GlaxoSmithKline (GSK)have signed a research collaboration and license agreement to develop newtherapeutic antibodies that promote an immune system attack against cancer. Specifically, the deal terms stipulate that MD Anderson grantsGSK exclusive worldwide rights to develop and commercialize the antibodies,which activate OX40 on the surface of T cells. MD Anderson, through its new Institute for AppliedCancer Science (IACS), will collaborate with GSK to conduct preclinicalresearch on the antibodies.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of a multicolored protein structure composed of folded ribbon-like strands against a blue and teal background with scattered spherical particles
Learn how advanced analytical methods support the characterization of antibody–C1q interactions and the qualification of analytical binding assays.